Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Morning post by Oncy on X (Twitter)

<< Previous

Bullboard Posts

Next >>

Post by jh1970on Mar 01, 2024 9:43am

170 Views

Post# 35908814

Morning post by Oncy on X (Twitter)

From Stocktwits . "Morning post by Oncy on X (Twitter) : Due to severe and unexpected travel disruptions, Oncolytics will not be presenting at the CAGLA Conference today. Our apologies to the event organizers and investors who had been planning to tune in." Is it true ?

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?